Sign in

CIK 0001281895

  • Non-accelerated filer
  • Smaller reporting company

ROCKET PHARMACEUTICALS, INC.

Sign in to watch
Ticker
RCKT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 646-440-9100
Business address
350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 10118
Former names
INOTEK PHARMACEUTICALS CORP
  1. 4 Open-market sale See Remarks sold 1,409 shares at $6.53 ($9,198)
  2. 4 Open-market sale See Remarks sold 1,582 shares at $6.53 ($10,327)
  3. 4 Open-market sale CEO sold 3,621 shares at $6.53 ($23,638)
  4. 4 Open-market sale General Counsel sold 946 shares at $6.53 ($6,175)
  5. 4 Open-market sale See Remarks sold 718 shares at $7.16 ($5,139)
  6. 4 Other acquisition Director acquired 14,220 shares (other)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Open-market buy CEO bought 20,000 shares at $5.08 ($101,600)
  9. 4 Open-market buy See Remarks bought 21,099 shares at $4.70 ($99,165)
  10. 4 Open-market sale Chief Financial Officer sold 7,489 shares at $5.29 ($39,647)
  11. 4 Open-market sale See Remarks sold 15,093 shares at an average $14.84 ($223,965)
  12. 4 Open-market sale See Remarks sold 6,078 shares at $10.58 ($64,305)
  13. 4 Open-market sale General Counsel sold 3,222 shares at $10.58 ($34,089)
  14. 4 Open-market sale See Remarks sold 2,737 shares at $10.58 ($28,957)
  15. 4 Open-market sale CEO sold 16,303 shares at $10.58 ($172,486)
  16. 4 Grant or award General Counsel acquired 90,358 shares (grant or award)
  17. 4 Grant or award CEO acquired 81,655 shares (grant or award)
  18. 4 Grant or award See Remarks acquired 80,318 shares (grant or award)
  19. 4 Grant or award See Remarks acquired 57,786 shares (grant or award)
  20. 4 Grant or award Chief Financial Officer acquired 90,358 shares (grant or award)

Page 5 of 21 · 406 filings